deltatrials
Terminated PHASE1 INTERVENTIONAL 2-arm NCT04933617

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Phase 1 Study of Copanlisib With Dose-adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Sponsor: National Cancer Institute (NCI)

Conditions Burkitt Lymphoma Diffuse Large B-Cell Lymphoma (DLBCL) Germinal Center B-cell Type (GCB) High-grade B-cell Lymphoma T-cell/Histocyte-rich Large B-cell Lymphoma
Interventions 18F-FDG - PET Bone Marrow Aspiration Bone Marrow Biopsy CT Scan Copanlisib Cyclophosphamide Doxorubicin ECHO EKG Etoposide Lumbar Puncture (LP) MRI Brain Prednisone Rituximab Vincristine
Updated 25 times since 2021 Last updated: Jun 13, 2024 Started: Mar 24, 2022 Primary completion: Nov 30, 2023 Completion: Nov 30, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated early because copanlisib was removed from the market by the Food and Drug Administration (FDA) and the manufacturer.

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

This PHASE1 trial investigates Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma (DLBCL) and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 25 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Sep 2023 · 3 months · monthly snapshot~Sep 2023 – ~Nov 2023 · 2 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

25 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Aug 2024 — Sep 2024 [monthly]

    Terminated PHASE1

    Status: Completed → Terminated

  3. Jul 2024 — Aug 2024 [monthly]

    Completed PHASE1

  4. Jan 2024 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. Dec 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

▶ Show 20 earlier versions

  1. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE1

  2. Sep 2023 — Nov 2023 [monthly]

    Recruiting PHASE1

  3. Jun 2023 — Sep 2023 [monthly]

    Recruiting PHASE1

  4. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE1

    Status: Suspended → Recruiting

  5. Apr 2023 — May 2023 [monthly]

    Suspended PHASE1

  6. Mar 2023 — Apr 2023 [monthly]

    Suspended PHASE1

  7. Feb 2023 — Mar 2023 [monthly]

    Suspended PHASE1

  8. Nov 2022 — Feb 2023 [monthly]

    Suspended PHASE1

  9. Sep 2022 — Nov 2022 [monthly]

    Suspended PHASE1

    Status: Recruiting → Suspended

  10. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  11. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

  12. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE1

  13. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE1

  14. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE1

  15. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  16. Jan 2022 — Feb 2022 [monthly]

    Not Yet Recruiting PHASE1

  17. Dec 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE1

  18. Nov 2021 — Dec 2021 [monthly]

    Not Yet Recruiting PHASE1

  19. Oct 2021 — Nov 2021 [monthly]

    Not Yet Recruiting PHASE1

  20. Sep 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations